Clovis Oncology Inc. (CLVS) Has Soared To A New High On Phase 3 Study Results

Shutterstock photo

( - Clovis Oncology Inc. ( CLVS ) announced Monday morning that its Phase 3 trial of rucaparib successfully achieved the primary endpoint of improved progression-free survival in patients with ovarian cancer.

Clovis Oncology has gapped open dramatically higher this morning and is now up 27.53 at $87.50 on above average volume. The stock has soared to a new high for the year.

For comments and feedback: contact

This article appears in: Stocks , Politics
Referenced Symbols: CLVS

More from RTT News


See headlines for CLVS

Follow on:

Research Brokers before you trade

Want to trade FX?